# Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

> **NCT01475162** · PHASE1,PHASE2 · TERMINATED · sponsor: **Medical College of Wisconsin** · enrollment: 14 (actual)

## Conditions studied

- Acute Graft Versus Host Disease

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01475162
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08-08
- **Primary completion:** 2016-02-17
- **Final completion:** 2018-09-29
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The DSMB felt the risks of the study now outweighed the potential benefits.
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475162, "Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01475162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*